netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Methotrexate found 36 matches

Formulary items 14 matches
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Methotrexate
(gastroenterology) 		Gastro-intestinal system - Drugs affecting the immune response - 01.05.03
  Cytotoxic Drug Methotrexate
(respiratory) 		Respiratory system - Antifibrotics - 03.11
  Cytotoxic Drug Methotrexate
(neurology) 		Central nervous system - Miscellaneous - 04.12
  Cytotoxic Drug Methotrexate
(oncology) 		Malignant disease and immunosuppression - Antimetabolites - 08.01.03
  Cytotoxic Drug Methotrexate
(Rheumatology) 		Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Cytotoxic Drug Methotrexate
(ophthalmology) 		Eye - Other anti-inflammatory preparations - 11.04.02
  Cytotoxic Drug Methotrexate
(dermatology) 		Skin - Drugs affecting the immune response - 13.05.03
  Calcium Folinate Malignant disease and immunosuppression - Drugs for cytotoxic-induced side-effects - 08.01
  Calcium folinate (Folinic Acid)
(Poisoning) 		Emergency Treatment of Poisoning - Poisoning - 16
  Etanercept Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Glucarpidase  (Voraxaze®) Malignant disease and immunosuppression - Drugs for cytotoxic-induced side-effects - 08.01
  Guselkumab  (Tremfya) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Rituximab Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Tocilizumab  (RoActemra®) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (04.12)
link in drug section MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (01.05.03)
link in drug section MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (08.01.03)
link in drug section MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (10.01.03)
link in drug section MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (13.05.03)
link in drug section MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (03.11)
link in drug section MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (11.04.02)
link in drug section MHRA Drug Safety Update (Sept 2020): Methotrexate once weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (04.12)
link in drug section MHRA Drug Safety Update (Sept 2020): Methotrexate once weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (11.04.02)
link in drug section MHRA Drug Safety Update (Sept 2020): Methotrexate once weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (01.05.03)
link in drug section MHRA Drug Safety Update (Sept 2020): Methotrexate once weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (08.01.03)
link in drug section MHRA Drug Safety Update (Sept 2020): Methotrexate once weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (03.11)
link in drug section MHRA Drug Safety Update (Sept 2020): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (13.05.03)
link in drug section MHRA Drug Safety Update (Sept 2020): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (10.01.03)
link in drug section NENC Shared Care Protocol - Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care) (03.11)
link in drug section NENC Shared Care Protocol - Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care) (08.01.03)
link in drug section NENC Shared Care Protocol - Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care) (01.05.03)
link in drug section NENC Shared Care Protocol - Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care) (13.05.03)
link in drug section NENC Shared Care Protocol - Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care) (04.12)
link in drug section NENC Shared Care Protocol - Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care) (10.01.03)
link in drug section NENC Shared Care Protocol - Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care) (11.04.02)
link in drug section NHS England: Glucarpidase for the urgent treatment of methotrexateinduced renal dysfunction (08.01)


 
netFormulary